120 related articles for article (PubMed ID: 21295466)
1. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
Isaacs RC; Newton CL; Cutrona KJ; Mercer SP; Dorsey BD; McDonough CM; Cook JJ; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Lynch JJ; Miller-Stein C; Michener MT; Wallace AA; White RB; Wong BK
Bioorg Med Chem Lett; 2011 Mar; 21(5):1532-5. PubMed ID: 21295466
[TBL] [Abstract][Full Text] [Related]
2. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
Burgey CS; Robinson KA; Lyle TA; Sanderson PE; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Williams PD; Coburn CA; Dorsey BD; Barrow JC; Stranieri MT; Holahan MA; Sitko GR; Cook JJ; McMasters DR; McDonough CM; Sanders WM; Wallace AA; Clayton FC; Bohn D; Leonard YM; Detwiler TJ; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP
J Med Chem; 2003 Feb; 46(4):461-73. PubMed ID: 12570369
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
[TBL] [Abstract][Full Text] [Related]
5. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
[TBL] [Abstract][Full Text] [Related]
6. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Baskin EP; Woltmann R; Lynch JJ; Lyle EA; Appleby SD; Chen IW; Dancheck KB; Vacca JP
J Med Chem; 1997 May; 40(11):1565-9. PubMed ID: 9171866
[TBL] [Abstract][Full Text] [Related]
7. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
Kreutter KD; Lu T; Lee L; Giardino EC; Patel S; Huang H; Xu G; Fitzgerald M; Haertlein BJ; Mohan V; Crysler C; Eisennagel S; Dasgupta M; McMillan M; Spurlino JC; Huebert ND; Maryanoff BE; Tomczuk BE; Damiano BP; Player MR
Bioorg Med Chem Lett; 2008 May; 18(9):2865-70. PubMed ID: 18420408
[TBL] [Abstract][Full Text] [Related]
8. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.
Sanderson PE; Lyle TA; Cutrona KJ; Dyer DL; Dorsey BD; McDonough CM; Naylor-Olsen AM; Chen IW; Chen Z; Cook JJ; Cooper CM; Gardell SJ; Hare TR; Krueger JA; Lewis SD; Lin JH; Lucas BJ; Lyle EA; Lynch JJ; Stranieri MT; Vastag K; Yan Y; Shafer JA; Vacca JP
J Med Chem; 1998 Nov; 41(23):4466-74. PubMed ID: 9804686
[TBL] [Abstract][Full Text] [Related]
9. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
[TBL] [Abstract][Full Text] [Related]
11. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors.
Lee L; Kreutter KD; Pan W; Crysler C; Spurlino J; Player MR; Tomczuk B; Lu T
Bioorg Med Chem Lett; 2007 Nov; 17(22):6266-9. PubMed ID: 17889527
[TBL] [Abstract][Full Text] [Related]
12. 9-hydroxyazafluorenes and their use in thrombin inhibitors.
Stauffer KJ; Williams PD; Selnick HG; Nantermet PG; Newton CL; Homnick CF; Zrada MM; Lewis SD; Lucas BJ; Krueger JA; Pietrak BL; Lyle EA; Singh R; Miller-Stein C; White RB; Wong B; Wallace AA; Sitko GR; Cook JJ; Holahan MA; Stranieri-Michener M; Leonard YM; Lynch JJ; McMasters DR; Yan Y
J Med Chem; 2005 Apr; 48(7):2282-93. PubMed ID: 15801822
[TBL] [Abstract][Full Text] [Related]
13. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.
Wang G; Goyal N; Hopkinson B
Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.
Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Sisko JT; Lynch JJ; Lyle EA; Baskin EP; Woltmann RF; Appleby SD; Chen IW; Dancheck KB; Naylor-Olsen AM; Krueger JA; Cooper CM; Vacca JP
J Med Chem; 1997 Oct; 40(22):3687-93. PubMed ID: 9357536
[TBL] [Abstract][Full Text] [Related]
15. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
[TBL] [Abstract][Full Text] [Related]
16. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
[TBL] [Abstract][Full Text] [Related]
17. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
[TBL] [Abstract][Full Text] [Related]
18. Efforts toward oral bioavailability in factor VIIa inhibitors.
Vijaykumar D; Rai R; Shaghafi M; Ton T; Torkelson S; Leahy EM; Riggs JR; Hu H; Sprengeler PA; Shrader WD; O'Bryan C; Cabuslay R; Sanford E; Gjerstadt E; Liu L; Sukbuntherng J; Young WB
Bioorg Med Chem Lett; 2006 Jul; 16(14):3829-32. PubMed ID: 16650987
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
[TBL] [Abstract][Full Text] [Related]
20. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
